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Summary
OBJECTIVE: To describe the epidemiology of tuberculosis
in Switzerland from 2009 to 2019.
METHODS: Analysis of Swiss notification data.
RESULTS: Tuberculosis cases declined from 553 (7.1/
100,000) in 2009 to 437 (5.1/100,000) in 2019. The male-
to-female ratio was 3:2. Although the number of tuberculo-
sis cases of Swiss origin has steadily declined, the number
of tuberculosis cases of foreign origin was rather stable
but peaked in 2016. Overall, three quarters of tuberculo-
sis cases were among people of foreign origin; of these,
around half were from East Africa, Southern East Europe,
and Southern Asia. Forty-nine percent had extrapul-
monary manifestations. Every year, with little variation,
7–16 cases with rifampicin resistance were reported (2.9%
overall). Independent risk factors for rifampicin resistance
were prior anti-tuberculosis treatment, with an adjusted
odds ratio (aOR) of 5.5 and a 95% confidence interval
(CI) from 3.7 to 8.1, and foreign origin (aOR 3.6, 95%
CI 2.0–7.0), particularly Georgia (aOR 10.0, 95% CI
4.0–23.1), Ethiopia (aOR 9.4, 95% CI 3.5–24.2), Tibet
(aOR 6.9; 95% CI 2.9–16.6) and Somalia (aOR 8.1, 95%
CI 4.0–17.2), together with Eritrea (aOR 2.6, 95% CI
1.1–5.9), accounting for more than half of all 134 cases .
From 2016 to 2018, applying the World Health Organiza-
tion definitions, overall treatment success in culture-con-
firmed pulmonary cases was 78%, and thus below the tar-
get of 85%. Since most cases with unsuccessful outcome
are due to missing information, the proportion of unsuc-
cessful outcome are overestimated.
CONCLUSION: Autochthonous tuberculosis has become
rare in Switzerland and the new diagnoses are increas-
ingly attributable to immigration. Rifampicin resistance re-
mains rare. Switzerland currently fails to achieve interna-
tional targets for treatment success.
Introduction
Tuberculosis is a communicable disease caused by path-
ogenic species of the Mycobacterium tuberculosis com-
plex. It is largely transmitted by the airborne route via
droplets produced by respiratory manoeuvres (predomi-
nantly coughing). Its manifestations result in tuberculosis
that may involve any extrapulmonary site in addition to
the predominant pulmonary form. Houben and Dodd esti-
mated that about one quarter of the world’s population is
latently infected with M. tuberculosis and thus at risk of
developing tuberculosis [1]. With early diagnosis and cor-
rect anti-tuberculosis treatment, virtually all cases are cur-
able, and transmission can be arrested promptly. The World
Health Organization (WHO) estimated a global incidence
of 130 per 100,000 inhabitants for 2019, a 9% reduction
since 2015 [2].
Tuberculosis and M. tuberculosis isolation are notifiable in
Switzerland, whereas latent infection with M. tuberculo-
sis is not. Since 1988, the Swiss Federal Office of Public
Health (FOPH) systematically collects tuberculosis data in
the national infectious disease surveillance system. Infor-
mation on drug susceptibility data is available since 1995.
WHO treatment outcome monitoring was implemented in
2016.
In this paper, we describe:
1. the national epidemiology of tuberculosis from 2009 to
2019;
2. key drug susceptibility test results from 2009 to 2019;
3. treatment outcome monitoring according to WHO,
from 2016 to 2018.
Materials and methods
Notification system and collected variables
Physicians and laboratories are legally mandated to report
a defined set of diseases and pathogens. Physicians report
to the cantonal medical service (sub-national level), which
forwards the reports to the FOPH (national level). Labo-
ratories notify the cantonal medical service and in paral-
lel the FOPH [3]. All information on a disease or pathogen
is centrally linked and consolidated in a single database
[4].
Physicians have to report information on age, gender,
country of birth, nationality, affected organs, prior tuber-
culosis diagnosis and treatment, treatment start, and drugs
used, as well as the type of applied diagnostics, (mi-
croscopy, nucleic acid amplification testing and culture).
Since 2016, physicians have to report treatment outcomes
according to the WHO recommendation [5].
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Laboratories have to notify results from microscopy, nu-
cleic acid amplification tests (such as the commercially
available Xpert® MTB/RIF assay or others), culture,
species and susceptibility/resistance for isoniazid, ri-
fampicin, pyrazinamide and ethambutol. In addition to the
mandatory notification, they must forward all rifampicin-
resistant strains to the Swiss National Reference Centre
for Mycobacteria. The National Reference Centre analyses
all rifampicin-resistant isolates and determines the suscep-
tibility pattern in these for first- and second-line drugs.
It also organises national quality assurance assessment
schemes for microscopy, culture and first-line drug suscep-
tibility testing.
Upon request, the Swiss Lung Association and its cantonal
branches support the cantonal medical service. The Asso-
ciation also supports the FOPH by compiling and updat-
ing tuberculosis guidelines in collaboration with the pro-
fessional medical organisations and compiles the data on
contact tracing.
Definitions
The Swiss case definition for tuberculosis is met if either
laboratory or clinical confirmation (or both) are present. A
case of tuberculosis is laboratory-confirmed if: (1) at least
one culture is positive for a pathogenic species of the M.
tuberculosis complex, or (2) if there is evidence for spe-
cific genetic components (from nucleic acid amplification
tests such as the WHO recommended Xpert® MTB/RIF as-
say or others) in conjunction with microscopic evidence of
mycobacteria in a respiratory sample.
A case is clinically confirmed if a physician decides to treat
a patient with at least three anti-tuberculosis drugs.
Repeat cases are defined as a new episode of tuberculosis
occurring more than 12 months after the initial notifica-
tion.
Origin refers to the country of birth if known. If country
of birth is unknown, nationality is used instead. If both
are missing, origin is missing as well. This results in the
following categories: Swiss (including the Principality of
Liechtenstein), foreign and unknown origin. The FOPH
defines world regions according to the Swiss Federal Sta-
tistical Office [6].
In this report, ‘year’ refers to the year of treatment start; if
this information is missing, the year of first laboratory ev-
idence is used instead. This approach differs from earlier
publications [3], where the reporting year was used [7].
This leads to minor differences when comparing data from
earlier publications [3].
Resistance to both isoniazid and rifampicin defines mul-
tidrug-resistant (MDR) tuberculosis. MDR strains are
termed extensively drug-resistant (XDR) if there is addi-
tional resistance to both a fluoroquinolone and at least one
of the injectable second-line drugs. The present analysis
focuses on rifampicin resistance [5], because this resistant
pattern is relevant for the choice of treatment, it is easy
and quick to diagnose by means of the broad application of
molecular technics (e.g., GenXpert), and about 80 per cent
of rifampicin resistant strains are also MDR.
The purpose of treatment outcome monitoring is to evalu-
ate national tuberculosis programmes. Treatment outcomes
are defined in accordance with WHO guidelines [5].
Cured: A pulmonary tuberculosis patient with bacteriolog-
ically confirmed tuberculosis at the beginning of treatment
who was smear- or culture-negative in the last month of
treatment and on at least one previous occasion.
Treatment completed: A tuberculosis patient who complet-
ed treatment without evidence of failure but with no record
to show that sputum smear or culture results in the last
month of treatment and on at least one previous occasion
were negative, either because tests were not done or be-
cause results are unavailable.
Treatment failed: A tuberculosis patient whose sputum
smear or culture is positive at month 5 or later during treat-
ment.
Died: A tuberculosis patient who dies for any reason be-
fore starting or during the course of treatment.
Lost to follow-up: A tuberculosis patient who did not start
treatment or whose treatment was interrupted for 2 consec-
utive months or more.
Not evaluated: A tuberculosis patient for whom no treat-
ment outcome is assigned. This includes cases “transferred
out” to another treatment unit as well as cases for whom
the treatment outcome is unknown to the reporting unit.
Treatment success: The sum of ‘cured’ and ‘treatment
completed’.
In this publication we report the WHO combined outcome
of ‘treatment success’. The FOPH collects treatment out-
come data at 12 months after start of treatment in non-
MDR and after 24 months in MDR tuberculosis cases.
Therefore, based on data up to 31 December 2019, our
analysis of treatment outcomes is limited to the 3-year pe-
riod from 2016 to 2018 among non-MDR tuberculosis cas-
es. The FOPH has published on MDR tuberculosis else-
where [8]. In this publication we summarise the outcome
data on rifampicin-susceptible tuberculosis since suscepti-
bility to rifampicin is the key determinant for the efficacy
of the first-line standard treatment regimen [9]. We further
defined a second composite outcome called ‘programmat-
ically unsuccessful treatment’ as the sum of ‘treatment
failed’, ‘lost to follow-up’ and ‘not evaluated’ but exclud-
ing ‘died’ from the numerator.
Statistics
The statistical methods include the determination of num-
bers and proportions, medians and quartiles. Linear trends
in the annual number of cases were estimated by gener-
alised linear models with the annual case numbers as re-
sponse and the reporting year as predictor. The results are
presented as the change in percent per year. One was sub-
tracted from the exponentiated regression coefficient, and
this difference was multiplied by 100 in order to express
the change in percent per year over time. Ninety-five per-
cent confidence intervals (CIs) were estimated by profil-
ing the log-likelihood. The change in the proportion of
tuberculosis cases of male gender was estimated by a sim-
ple linear regression model with the proportion of men
among cases as response and the reporting year as predic-
tor. CIs were estimated by standard least square methods
expressing the change over time in percent points. This re-
sult was validated by the standard test for trend in pro-
portion made available by the prop.trend.test in the stats
library in R. Risk factors for Rifampicin resistance were
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estimated using univariable and multivariable logistic re-
gression, considering origin and prior treatment as prima-
ry risk factors. In the basic model we used origin as a bi-
nary variable (Swiss vs foreign) and added an interaction
term of prior treatment and origin. In the extended model
we used origin as a country-specific variable, with Switzer-
land as reference. Statistical inference was done by means
of 95% confidence limits. Notched boxplots were com-
piled for the age distribution [10]. All analyses were done
with R 4.0.2 under Windows [11].
Legal basis
The Swiss epidemic law (EpidA SR 818.101, EpidO SR
818.101.1 FPHA-ORD SR 818.101.126), forms the legal
framework for collecting, analysing and reporting notifica-
tion data in an anonymized format. Ethics clearance was
not required.
Results
The annual number of tuberculosis cases decreased from
553 in 2009 to 437 in 2019 (table 1 and fig. 1), correspond-
ing to annual incidences of 7.1 and 5.1 cases per 100,000
inhabitants, respectively. The Swiss case definition for tu-
berculosis is met if laboratory or clinical criteria are met.
For details see ‘Materials and methods’.
The average decline of overall annual case numbers was
−0.84% (95% CI −1.63% to −0.03%). The overall decline
was mainly attributable to persons of Swiss origin (average
decline of annual number −3.63%, 95% CI −5.26 to
−1.98%), whereas the number of cases involving persons
of foreign origin remained fairly stable over the obser-
vation period (average decline of annual number −0.08%,
95% CI −1.01 to +0.87%), peaking in 2016 with respect
to people originating from high-incidence countries (par-
ticularly Eritrea). The declining trend among persons of
Swiss origin becomes much clearer when previous
years, 1995–2008, are included in addition to our selected
time frame 2009–2019 (supplementary fig. S1 in the ap-
pendix).
Figure 1: Annual numbers of tuberculosis, by origin, in Switzer-
land and Liechtenstein 2009–2019. 
The Swiss case definition for tuberculosis is met if laboratory or 
clinical criteria are met. For de-tails see ‘Materials and methods’.
Patient characteristics
The large majority (73.8%) of tuberculosis cases in
Switzerland was acquired abroad, in immigrants from
countries with a high incidence of tuberculosis. Most for-
eign tuberculosis patients immigrated from Eastern Africa
(28%), South-East Europe (12%) and Southern Asia (9%)
(fig. 2). When cases with missing information were ex-
cluded, patients from these three world regions made up
52% of all with foreign origin. The eight most affected
countries were Eritrea (n = 685), Somalia (n = 420), Portu-
gal (n = 232), Kosovo (n = 179), Tibet (China) (n = 156),
India (n = 140), Sri Lanka (n = 128) and Ethiopia (n
= 110). These eight contribute 47.4% of notifications
among those of foreign origin with known provenance.
The proportion of men slightly declined from 57% in 2009
to 54% in 2019 (annual average linear decline in per cent
points −0.61%, 95% CI −1.16 to −0.06%), whereas that of
women slightly increased from 43% to 46% (p for trend
<0.01). On average, there were more male (58%) than fe-
male cases (42%).
The median age undulated between 37 and 38 years over
the observation period. Fifty percent were aged between 26
and 60 years (table 1). The age distribution over the last
11 years mirrors the fact that young men dominate the de-
mographics in the migrating population (fig. 3). The age
distribution was dominated by young adult men in persons
of foreign origin. Elderly adults dominated the age distri-
bution in persons of Swiss origin. The difference between
men and women was less marked. The number of noti-
fied cases in children of Swiss origin below the age of 5
years (n = 89) is attributable to our definition of origin,
and mostly concerns children of immigrants from high-in-
cidence countries.
Figure 2: Distribution of foreign regions of origin among tuberculo-
sis cases in Switzerland and Liechtenstein, 2009–2019. 
Eastern Africa includes Eritrea, Somalia, Ethiopia, Kenya, and 
Tanza-nia; South-East Europe Kosovo, Serbia, Montenegro, 
Bosnia and Herzegovina, Macedonia, Romania, Albania, Croatia, 
Bulgaria, and Slovenia; Southern Asia India, Sri Lanka, 
Afghanistan, Pak-istan, Nepal, and Bangladesh. The country of 
origin was missing in 216 cases (see table 1), and in 27 cases 
origin was reportedly non-Swiss, but without specifying the country.
Original article Swiss Med Wkly. 2021;151:w30032
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 9
As expected, cantons with the largest populations also re-
ported most of the cases (table 1).
Site of disease
Seventy-one percent of all cases manifested as pulmonary
tuberculosis (50% exclusively pulmonary, 21% pulmonary
and extrapulmonary), in 28% the manifestation was ex-
clusively extrapulmonary, and in 1%, the manifestation
site was unknown (tables 1 2). The most frequently noti-
fied extrapulmonary sites were extra-thoracic lymphatic (n
= 987, 16.7%), intrathoracic lymphatic (n = 838, 14.2%)
and pleural (n = 535, 9.1%). Disseminated tuberculosis oc-
curred in 414 cases (7.0%) and the central nervous system
was involved in 111 cases (1.9%) – both disease manifesta-
tions are considered clinically particularly problematic. At
least one of those two problematic manifestations was pre-
sent in 479 cases (8.1%).
Rifampicin resistance and respective risk factors
Since 1995, at least one isolate from each culture-positive
case was subject to phenotypic drug susceptibility testing
for at least isoniazid and rifampicin. Genotypic drug sus-
ceptibility testing for rifampicin has become more widely
available since 2010 [12]. The annual number of ri-
fampicin-resistant tuberculosis cases varied between 7 and
16. From 2009 to 2019, 134 cases of rifampicin resistance
with known origin were reported (table 1). This corre-
sponds to an overall rifampicin resistance rate of 2.9%
(134 out of 4625). Eleven cases were persons of Swiss ori-
gin corresponding to 1.1% out of 1045 Swiss cases tested.
Main risk factors were foreign origin (n = 123 out of 3994,
3.4%) and prior anti-tuberculosis treatment (n = 41 out of
341, 10.7%).
Origin and prior anti-tuberculosis treatment were indepen-
dent risk factors in the logistic regression, i.e. the inter-
action term showed an adjusted odds ratio (aOR) of 1.5,
but with a large 95% CI of 0.4 to 7.2) and therefore at-
tributable to chance alone, which is why we estimated
Figure 3: Age distribution, by sex and origin, of tuberculosis cases
in Switzerland and Liechtenstein, 2009–2019.
the model without interaction term (table 3). The aOR
comparing foreign versus Swiss origin was 3.6 (95% CI
2.7–7.0) and prior anti-tuberculosis treatment versus no or
unknown treatment status 5.5 (3.7–8.1). Persons from So-
malia (n = 27 out of 355, 7.6%), Eritrea (n = 13 out of 561,
2.3%), Tibet (China) (n = 11 out of 136, 8.1%) und Geor-
gia (n = 9 out of 32, 28.1%) accounted for 60 out of 134
cases (49.0%). In the extended model using Swiss origin
as reference and keeping prior anti-tuberculosis treatment
as confounder (aOR 4.5, 95% CI 3.0–6.7), we obtained
the following aORs (95% CI): Georgia 10.0 (4.0–23.1),
Ethiopia 9.4 (3.5–24.2), Tibet (China) 6.9 (2.9–16.6), So-
malia 8.1 (4.0–17.2), Eritrea 2.6 (1.1–5.9,) sorted by de-
creasing order. The remaining countries show an increased
aOR of 2.3 with a 95% CI of 1.2–4.7.
Overall, 117 out of 134 cases (87%) were MDR, and 4
of the MDR cases were XDR. All four XDR cases were
among persons of foreign origin: Moldova, Morocco, Chi-
na, Georgia. The annual number of MDR cases varied be-
tween four and fourteen cases in the observation period
without a clear trend.
Treatment outcome monitoring 2016–2018, according
to WHO definitions
Data on treatment outcome monitoring were available for
the 3 years 2016 to 2018. Treatment success (cured or
treatment completed) increased slightly from 77% to 80%
among laboratory-confirmed pulmonary, rifampicin-sus-
ceptible tuberculosis cases (table 4). Adolescents and el-
derly patients were less likely to achieve treatment success
(table 5). With the possible exception of adolescents,
women had a slightly higher proportions of treatment suc-
cess than men. Death (of any cause) was rare (4.4%).
The yearly proportion of patients with programmatically
unsuccessful treatment slightly decreased from 20.2% in
2016 to 15.5% in 2018. The highest single contributor to
this composite outcome was the proportion of ‘not evalu-
ated’ at 80.8% of unsuccessful treatments. This suggests
that motivating clinicians to fill in notification forms more
completely might already lead to meeting WHO targets.
Discussion
Over the past 11 years 2009–2019, tuberculosis notifica-
tions in Switzerland and Liechtenstein have decreased to
an incidence of 5.1 cases per 100,000 in 2019. Most cas-
es are found among immigrants from countries with a
high incidence of tuberculosis, particularly Eritrea, Soma-
lia and Ethiopia. Within Europe, Portugal and Kosovo are
the most important countries of origin of tuberculosis pa-
tients in Switzerland. Previous analyses of tuberculosis in
Switzerland had shown a similar trend [13].
The decreasing trend in the total number of notified tuber-
culosis cases fits with that observed most notably in oth-
er industrialised countries [2, 14–16]. In contrast to this
favourable development, trends in lower income countries
have been declining too slowly to achieve the targets of the
WHO “End TB strategy” in a timely fashion [17].
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Table 1:
Summary of tuberculosis cases in Switzerland and Liechtenstein, 2009–2019.
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Total Percent
Overall cases (Swiss case definition*) 553 543 587 486 542 495 565 626 557 511 437 5902 100.0
– Clinically confirmed 529 509 548 456 516 448 523 584 510 479 409 5511 93.4
– Laboratory-confirmed 460 457 484 411 464 434 478 537 474 440 373 5012 84.9
– Both 436 423 446 381 438 387 436 495 428 408 346 4624 78.3
– Repeat case 6 7 12 14 16 12 12 12 11 14 10 126 2.1
Age
Median 37 36 38 37 37 37 35 31 34 36 38 36 n.a.
Lower Quartile 26 27 26 28 27 26 24 22 23 25 27 25 n.a.
Upper Quartile 58 56 54 59 55 52 53 47 51 56 58 54 n.a.
Gender
Male 313 296 350 265 291 312 340 401 352 308 238 3466 58.7
Female 240 247 237 221 251 183 225 225 205 203 199 2436 41.3
Origin
Switzerland/Liechtenstein 144 156 141 109 128 103 122 102 115 115 98 1333 22.6
Foreign 395 363 428 359 400 369 423 496 419 381 320 4353 73.8
Unknown 14 24 18 18 14 23 20 28 23 15 19 216 3.7
Canton
AG 29 33 32 20 25 22 39 48 41 34 35 358 6.1
AR 4 5 4 2 1 3 2 1 22 0.4
BE 53 49 69 40 59 56 55 66 55 48 35 585 9.9
BL 17 9 13 11 15 8 10 15 19 16 8 141 2.4
BS 22 25 26 25 27 17 21 21 17 21 15 237 4.0
FR 18 16 8 18 12 10 15 13 14 19 12 155 2.6
GE 64 48 66 54 60 53 68 74 54 47 47 635 10.8
GL 2 3 3 1 1 1 1 2 14 0.2
GR 5 11 4 8 14 8 17 15 10 9 10 111 1.9
JU 2 3 11 2 2 10 9 5 5 7 5 61 1.0
LU 29 22 26 12 20 23 23 15 27 22 17 236 4.0
NE 14 11 12 8 7 13 14 14 16 11 8 128 2.2
NW 2 2 1 1 1 2 2 11 0.2
OW 1 5 2 2 1 1 1 2 1 2 18 0.3
SG 24 23 32 32 17 27 18 34 28 13 21 269 4.6
SH 4 3 7 3 6 7 4 5 4 9 8 60 1.0
SO 17 17 14 7 9 13 15 14 15 14 10 145 2.5
SZ 10 11 5 6 5 10 6 7 7 7 4 78 1.3
TG 11 15 15 11 17 13 11 17 8 9 10 137 2.3
TI 23 24 22 16 18 25 40 51 33 29 9 290 4.9
VD 65 77 93 70 83 55 76 60 76 72 52 779 13.2
VS 20 12 12 17 27 22 13 15 20 19 14 191 3.2
ZG 15 11 7 5 7 7 8 5 6 4 5 80 1.4
ZH 100 112 101 107 106 87 92 123 97 94 105 1124 19.0
AI 1 1 1 2 1 6 0.1
UR 2 2 1 2 3 1 1 1 2 1 16 0.3
Principality of Liechtenstein 2 2 3 1 2 2 1 1 1 15 0.2
Site of disease
Pulmonary only 274 289 299 256 286 262 278 304 265 253 207 2973 50.4
Pulmonary and extrapulmonary 108 105 109 89 105 88 135 139 125 114 97 1214 20.6
Extrapulmonary only 166 141 172 136 143 141 143 173 161 138 126 1640 27.8
Unknown 5 8 7 5 8 4 9 10 6 6 7 75 1.3
All pulmonary cases 382 394 408 345 391 350 413 443 390 367 304 4187 100.0
– Culture confirmed 327 337 333 303 340 310 345 384 329 313 257 3578 85.5
– Culture confirmed rifampicin susceptible cases 317 326 319 293 322 288 326 341 307 304 244 3387 80.9
Drug resistance (cases tested for rifampicin)‡ 437 426 449 383 440 402 439 471 427 407 344 4625 100.0
– Rifampicin-susceptible 430 415 438 375 423 385 423 454 415 399 334 4491 97.1
– Rifampicin-resistant, foreign origin 7 11 10 7 15 14 14 16 12 8 9 123 2.7
– Rifampicin-resistant, Swiss origin 0 0 1 1 2 3 2 1 0 0 1 11 0.2
AG: Aargau; AR: Appenzell Ausserrhoden; BE: Bern; BL: Basel-Landschaft; BS: Basel-Stadt; FR: Fribourg; GE: Geneva; GL: Glarus; GR: Graubünden; JU; Jura; LU: Lucerne;
NE: Neuchâtel; NW: Nidwalden; OW: Obwalden; SG: St Gallen; SH: Schaffhausen; SO: Solothurn; SZ: Schwyz ; TG: Thurgau; TI: Ticino; VD: Vaud; VS: Valais; ZG: Zug; ZH:
Zurich; AI: Appenzell Innerrhoden; UR: Uri
* The Swiss case definition for tuberculosis is met if laboratory or clinical criteria are met. For details see ‘Materials and methods’. ‡ only cases with known origin and rifampicin
susceptibility test result
Original article Swiss Med Wkly. 2021;151:w30032
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 9
The age distribution mirrors the demography of patients of
foreign origin as observed in previous analyses [3]. Char-
acteristically, migrants with tuberculosis entering Switzer-
land are nowadays young adult men from Eritrea and So-
malia (largely refugees and asylum seekers) and from
Portugal (directly joining the workforce). The FOPH offers
a web-based platform with 10 key questions about tuber-
culosis contextual factors (www.tb-screen.ch). This online
tool is available in the 34 languages most relevant to asy-
lum seekers in Switzerland and has been validated for sup-
porting clinicians in taking a tuberculosis-specific medical
history [18]. Unfortunately, data on immigrant screening
Table 2:
Site of disease, tuberculosis cases in Switzerland and Liechtenstein, 2009–2019.
Site of disease N Percent a
Pulmonary 4187 70.9
Pleural 535 9.1
Lymphatic, intrathoracic 838 14.2
Lymphatic, extrathoracic 987 16.7
Osteo-articular, spine 188 3.2
Osteo-articular, other 109 1.9
Central nervous system, meningeal 64 1.1
Central nervous system, other 61 1.0
Central nervous system, allb 111 1.9
Disseminatedc 414 7.0
Other sites 313 5.3
Site not specified 75 1.3
a Percentages do not add up to 100 owing to overlapping categories. The denominator is n = 5902.
b Numbers and percent are not the sum of meningeal and central nervous system involvement owing to overlapping categories.
c Includes acute and protracted, i.e. miliary, mycobacteraemia, and polytopic (three or more sites affected)
Tabler 3:
Rifampicin resistance risk factor models, Switzerland and Liechtenstein, 2009–2019.
Univariable Multivariable Multivariable
OR 2.5% 97.5% aOR 2.5% 97.5% aOR 2.5% 97.5%
Basic Model
Prior treatment No Ref. Ref. Ref.
Yes 5.4 3.6 7.8 3.9 0.8 13.6 5.5 3.7 8.1
Origin Swiss Ref. Ref. Ref.
Foreign 3.4 1.9 6.7 3.2 1.6 7.1 3.6 2.0 7.0
Interaction term 1.5 0.4 7.2
Extended Model
Prior treatment No Ref. Ref.
Yes 5.4 3.6 7.8 4.7 3.1 7.4
Origin Swiss Ref. Ref.
Somalia 7.7 3.9 16.4 8.1 4.0 17.2
Eritrea 2.2 1.0 5.1 2.6 1.1 5.9
Ethiopia 9.3 3.5 23.6 9.4 3.5 24.2
Tibet (China) 8.3 3.5 19.7 6.9 2.9 16.6
Georgia 16.6 7.0 36.4 10.0 4.0 23.1
Other 2.2 1.2 4.5 2.3 1.2 4.7
Table 4:
Treatment outcome monitoring according to WHO standards among pulmonary culture-positive, rifampicin-susceptible tuberculosis cases, Switzerland and Liechtenstein,
2016–2018.
2016 2017 2018 Total Percent
Cured 120 125 130 375 39.4
Treatment completed 143 111 114 368 38.7
Treatment failure 2 0 0 2 0.2
Lost to follow up 13 13 4 30 3.2
Not evaluated 54 38 43 135 14.2
Died 9 20 13 42 4.4
Total 341 307 304 952 100.0
Treatment success (WHO): Sum of Cured and Treatment completed
N 263 236 244 743 78.0
Percent 77.1 76.9 80.3
Programmatically unsuccessful: Sum of Treatment failure, Lost to follow-up and Not evaluated
N 69 51 47 167 17.5
Percent 20.2 16.6 15.5
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are no longer available since the revision of the Epidemic
Act in 2016. Therefore, we cannot anymore distinguish be-
tween asylum seekers and other groups of foreign origin.
Drug resistance to rifampicin – relevant to the indication
for second-line drugs – has fortunately remained rare in
Switzerland [3]. The two most important risk factors for
drug resistance are foreign origin, particularly Georgia, Ti-
bet (China), Somalia, Ethiopia and Eritrea, as well as a
history of previous anti-tuberculosis treatment [3, 4]. A
proper history of a pervious treatment is crucial for the
choice of an appropriate initial treatment regimen [19] and
must be accompanied by prompt drug susceptibility test-
ing. Since the introduction of genotyping methods, which
became widely available in 2010 [12], drug susceptibility
testing of rifampicin has been greatly applied, and results
are theoretically available within one working day [3]. It
has to be stressed here, that treating cases of rifampicin-
resistant tuberculosis requires specific medical training.
The Swiss Lung Association offers support by experienced
physicians and a closed user group for an anonymised dis-
cussion of specific cases. Rifampicin-susceptible tubercu-
losis without evidence of prior anti-tuberculosis treatment
may be treated by general practitioners if they comply with
the Swiss recommendations or under the supervision of a
well-trained colleague [9].
The FOPH included treatment outcome monitoring ac-
cording to WHO standards in the national notification sys-
tem with the revision of the Epidemics Act in 2016. The
overall treatment success in culture-confirmed, rifampicin-
susceptible, pulmonary tuberculosis was 78% (among the
952 cases with the relevant information), and thus below
the WHO target of 85%, largely because of missing data
(called ‘not evaluated’ in the WHO definitions). The Swiss
surveillance system does not record directly observed
treatment. Poor treatment adherence and high proportions
of loss to follow-up may be common in male adolescents,
and both has been described specifically for tuberculosis
treatment outcomes in Haiti and in South Africa [20, 21].
Immigrant adolescents with tuberculosis often come unac-
companied from a cultural background very different from
the Swiss context and may benefit from specific support
regarding adherence to medication.
The overall treatment success was similar in 1996, with a
success of 79% [22]; however, that article had been pub-
lished prior to the WHO recommendations in 2013 with
the 2020 revision [5], limiting direct comparison. With re-
gard to the current data, the proportion of patients with
treatment success may have slightly improved from
77% in 2016 and 2017 to 80% in 2018. WHO reporting us-
es an intention-to-treat approach. We propose using an ad-
ditional composite outcome ‘programmatically unsuccess-
ful’ as defined above and shown at the bottom of table 4,
excluding patients who died during the observation peri-
od from the numerator (but not the denominator). This ad-
ditional indicator might better reflect the performance of
national tuberculosis programme in countries where tuber-
culosis patients rarely die of tuberculosis, but rather of oth-
er causes. We observed a small but steady decline in this
composite outcome over the 3 years of observation. This
was paralleled by a decrease of missing information about
treatment outcome, showing slowly improved adherence
to notification guidelines. However, asylum seekers diag-
nosed with tuberculosis in national registration centres and
subsequently transferred to a specific canton that is differ-
ent from the canton of the registration centre often result in
‘loss to follow-up’.
With respect to tuberculosis notification rates 2015–19,
Switzerland is very similar to countries of the Western sub-
region of WHO Europe [23]; however, the estimated in-
cidence in Switzerland was lower than the European Eco-
nomic Area average (5.1 versus 10.6 per 100,000 in 2019)
[23]. Also the Swiss gender distribution is in accordance
with European data, with more men than women report-
ed in 2019. The percentage of foreign-born tuberculosis
cases is in line with comparable high-income immigration
countries such as Sweden, Norway or Denmark. Drug re-
sistance is a problem in the broad WHO European Region
(17.0% in 2019) but is not in Switzerland (1.1%) [23, p42].
As in Switzerland, previous treatment is a risk factor for
drug resistance. This fact is confirmed by our logistic re-
gression models (see table 3).
Switzerland is not alone in failing to meet the WHO ‘treat-
ment success’ target of 85%. This is explained by the large
number of ‘not evaluated’ cases, and there are countries
in the European region that are performing even worse
than Switzerland such as Finland, France and Denmark –
strongly suggesting that compiling treatment outcome data
in routine surveillance is an issue in Switzerland as well as
in other European countries.
A possible limitation to our analysis is a potential bias
that might be introduced by underreporting – a concern
of every notification system. However, no national studies
exist addressing this specific problem. The dual system
mandating both physicians and laboratories to report on
tuberculosis gives some assurance that at least the noti-
fication of laboratory-confirmed tuberculosis is likely to
be a good proxy for the incidence of tuberculosis diag-
noses. Because tuberculosis notification uses the patient’s
full name, the FOPH cannot collect potentially stigmatis-
ing medical risk factors such as human immunodeficiency
virus infection, alcoholism, or diabetes.
Table 5:
Treatment success according to the WHO (cured or treatment completed) among pulmonary culture-positive rifampicin-susceptible tuberculosis cases, Switzerland and Liecht-
enstein, 2016–2018.
Male Female Overall
Age Groups Success/total Percent Success/total Percent Success/total Percent
0–14 18/22 81.8 13/15 86.7 31/37 83.8
15–19 57/83 68.7 11/20 55.0 68/103 66.0
20–39 224/279 80.3 143/166 86.1 367/445 82.5
40–64 118/147 80.3 71/80 88.8 189/227 83.3
65+ years 49/81 60.5 39/59 66.1 88/140 62.9
Total 466/612 76.1 277/340 81.5 743/952 78.0
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Conclusion
Tuberculosis has become a rare disease in Switzerland, and
resistance to the key drug rifampicin remains fortunate-
ly rare among previously untreated patients. Twenty-eight
percent of tuberculosis cases exclusively concern extra-
pulmonary manifestations, therefore a normal chest radi-
ograph or negative cultures from respiratory samples do
not definitively exclude tuberculosis. In Switzerland, the
most important risk group for tuberculosis, both drug-sus-
ceptible and -resistant, are migrants from the Horn of
Africa, but also from South-East and South-West Europe.
A careful history of migration and previous treatment with
anti-tuberculosis drugs is essential for the appropriate
choice of the treatment regimen.
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Appendix: Supplementary figure
Figure S1: Annual numbers of tuberculosis, by origin, in Switzerland and Liechtenstein 1995–2019. The Swiss case definition for tuberculosis
is met if laboratory or clinical criteria are met. For details see ‘Materials and methods’.
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